ArticleCancer research2019
Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 45 citations in OpenAlex.
- Pancreatic ductal adenocarcinoma: integrating molecular insights for targeted interventions.Signal transduction and targeted therapy · 2026Review
- Expression and interaction of RNA binding protein HuR with multidrug transporters (P-GP, MRP1, and ABCG2) in chemoresistant breast and colorectal cancer cells.Journal, genetic engineering & biotechnology · 2025Article
- A Population-Specific PARP1 Gene Variation Modulates PARP Trapping.bioRxiv : the preprint server for biology · 2025Article
- BARD1: A Friend or Foe in Pancreatic Ductal Adenocarcinoma?International journal of molecular sciences · 2025Review
- Prospects for PARG inhibitors in cancer therapy.Journal of molecular cell biology · 2025Review
- ADP-ribose hydrolases: biological functions and potential therapeutic targets.Expert reviews in molecular medicine · 2024Review
- CHK1 inhibitor induced PARylation by targeting PARG causes excessive replication and metabolic stress and overcomes chemoresistance in ovarian cancer.Cell death discovery · 2024Article
- Article
- Review
- Strategies for the Management of Patients with Pancreatic Cancer with PARP Inhibitors.Cancer treatment and research · 2023Article
- Current Evidence and Future Perspectives about the Role of PARP Inhibitors in the Treatment of Thoracic Cancers.OncoTargets and therapy · 2023Review
- The RNA-Binding Protein HuR Posttranscriptionally Regulates the Protumorigenic Activator YAP1 in Pancreatic Ductal Adenocarcinoma.Molecular and cellular biology · 2022Article
- Accumulation of poly (adenosine diphosphate-ribose) by sustained supply of calcium inducing mitochondrial stress in pancreatic cancer cells.World journal of gastroenterology · 2022Article
- PARG suppresses tumorigenesis and downregulates genes controlling angiogenesis, inflammatory response, and immune cell recruitment.BMC cancer · 2022Article
- Article
- NADNAR cancer · 2021Article
- FAM49B promotes breast cancer proliferation, metastasis, and chemoresistance by stabilizing ELAVL1 protein and regulating downstream Rab10/TLR4 pathway.Cancer cell international · 2021Article
- Divulging the Critical Role of HuR in Pancreatic Cancer as a Therapeutic Target and a Means to Overcome Chemoresistance.Cancers · 2021Review
- PARP1-modulated chromatin remodeling is a new target for cancer treatment.Medical oncology (Northwood, London, England) · 2021Review
- AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy withMolecular cancer research : MCR · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 8 institutions in 3 countries.
Aditi JainThe Jefferson Pancreas, Biliary and Related Cancer Center, Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.
Lebaron C Agostini *The Jefferson Pancreas, Biliary and Related Cancer Center, Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.
Grace A McCarthy *The Jefferson Pancreas, Biliary and Related Cancer Center, Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.
Saswati N ChandSidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0000-0001-5625-0517
AnnJosette RamirezThe Jefferson Pancreas, Biliary and Related Cancer Center, Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.
Avinoam NevlerThe Jefferson Pancreas, Biliary and Related Cancer Center, Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0000-0002-5928-0559
Joseph CozzitortoThe Jefferson Pancreas, Biliary and Related Cancer Center, Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.
Christopher W SchultzThe Jefferson Pancreas, Biliary and Related Cancer Center, Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0000-0001-5731-2847
Cinthya Yabar LowderThe Jefferson Pancreas, Biliary and Related Cancer Center, Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0000-0003-4578-6011
Kate M SmithDrug Discovery Unit, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom.
Ian D WaddellDrug Discovery Unit, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom.
Maria Raitses-GurevichOncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel.
Chani StosselOncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel.
Yulia Glick GormanOncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel.
Dikla AtiasOncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel.ORCID 0000-0003-3362-025X
Charles J YeoThe Jefferson Pancreas, Biliary and Related Cancer Center, Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.
Jordan M WinterSurgical Oncology, University Hospitals Cleveland Medical Center, Cleveland, Ohio.
Kenneth P OliveDepartment of Medicine and Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York.
Talia GolanOncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel.
Michael J PishvaianDepartment of Gastrointestinal Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
Donald OgilvieDrug Discovery Unit, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom.
Dominic I JamesDrug Discovery Unit, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom.
Allan M JordanDrug Discovery Unit, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom.
Jonathan R BrodyThe Jefferson Pancreas, Biliary and Related Cancer Center, Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania. jonathan.brody@jefferson.edu.
Thomas Jefferson University · USCancer Research UK Manchester Institute · GBSheba Medical Center · ILTel Aviv University · ILColumbia University Irving Medical Center · USSidney Kimmel Cancer Center · USThe University of Texas MD Anderson Cancer Center · USUniversity Hospitals of Cleveland · US
Funding
X-Ray Crystallography and Macromolecular CharacterizationP30CA056036 · NCI · THOMAS JEFFERSON UNIVERSITY · PI Andrew Chapman · 1995 to 2026
$94.8MTargeting pancreatic cancer's metabolic addiction to HuRR37CA227865 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI WINTER, JORDAN M · 2018 to 2024
$2.7MTargeting HuR to improve a synthetic lethal therapy for pancreatic cancerR01CA212600 · NCI · THOMAS JEFFERSON UNIVERSITY · PI BRODY, JONATHAN · 2017 to 2021
$1.9MCancer Research UK 17098Cancer Research UK C480/A11411Cancer Research UK C5759/A17098NCI NIH HHS P30 CA056036NCI NIH HHS R01 CA212600NCI NIH HHS R37 CA227865
Abstract
Patients with metastatic pancreatic ductal adenocarcinoma (PDAC) have an average survival of less than 1 year, underscoring the importance of evaluating novel targets with matched targeted agents. We recently identified that poly (ADP) ribose glycohydrolase (PARG) is a strong candidate target due to its dependence on the pro-oncogenic mRNA stability factor HuR (
Indexed as
AnimalsCarcinoma, Pancreatic DuctalCell Line, TumorDNA DamageEnzyme InhibitorsFemaleGene SilencingGlycoside HydrolasesHumansMice, NudeMolecular Targeted TherapyOxaliplatinPancreatic NeoplasmsRecombinational DNA RepairSmall Molecule LibrariesXenograft Model Antitumor AssaysEnzyme InhibitorsGlycoside HydrolasesOxaliplatinpoly ADP-ribose glycohydrolaseSmall Molecule Libraries
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.